Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 601–700 of 1,002
Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
Chigbu, D. I., & Labib, B. A. (2021) · Pharmaceuticals · doi:10.3390/ph14070658 · Cited by 42
The Epidemiology and Clinical Presentations of Atopic Diseases in Selective IgA Deficiency
Morawska, I., Kurkowska, S., Bębnowska, D., Hrynkiewicz, R., Becht, R., Michalski, A., Piwowarska-Bilska, H., Birkenfeld, B., Załuska-Ogryzek, K., Grywalska, E., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173809 · Cited by 44
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
Lytvyn, Y., & Gooderham, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020568 · Cited by 42
“Interestingly, there appears to be a larger risk of conjunctivitis with dupilumab (up to 22% in phase III trials) compared to tralokinumab (~11%) or lebrikizumab (~3%) [22,23,87,88].”
BackgroundEmerging Systemic Treatments for Atopic Dermatitis
Ferrucci, S. M., Tavecchio, S., Marzano, A. V., & Buffon, S. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00920-4 · Cited by 40
Thomson, J., Wernham, A. G. H., & Williams, H. C. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16317 · Cited by 35
Dermatology today and tomorrow: from symptom control to targeted therapy
Blume‐Peytavi, U., Bagot, M., Tennstedt, D., Aroman, M. S., Stockfleth, E., Zlotogorski, A., Mengeaud, V., Schmitt, A.-M., Paul, C. F., Lim, H. W., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15335 · Cited by 38
Maintz, L., Welchowski, T., Herrmann, N., Brauer, J., Traidl‐Hoffmann, C., Havenith, R., Müller, S., Rhyner, C., Dreher, A., CK‐CARE study group, et al. (2023) · Allergy · doi:10.1111/all.15647 · Cited by 37
Self-citationBiologic Therapies for Asthma and Allergic Disease: Past, Present, and Future
Jiménez, F. R., Pavón-Romero, G. F., Velásquez-Rodríguez, J. M., López-Garza, M. I., Lazarini-Ruiz, J. F., Gutiérrez-Quiroz, K. V., & Teran, L. M. (2023) · Pharmaceuticals · doi:10.3390/ph16020270 · Cited by 38
“Reactions at the injection site and conjunctivitis were more frequent in the Dupilumab groups than in the placebo [98].”
BackgroundDupilumab-associated blepharoconjunctivitis
Paulose, S. A., Sherman, S. W., Glass, L. R. D., & Suh, L. H. (2019) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2019.100550 · Cited by 33
“This suggests a unique relationship between dupilumab use for atopic dermatitis and ocular complications rather than an inherent effect of dupilumab.(3,6) Studies have not revealed why the incidence of conjunctivitis and severity of its presentation varies with dupilumab use.”
BackgroundMethodInfluentialLee, Y., Kim, M., & Nahm, D. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.5.733 · Cited by 34
Le, M., Berman-Rosa, M., Ghazawi, F. M., Bourcier, M., Fiorillo, L., Gooderham, M., Guenther, L., Hanna, S., Hong, H., Landells, I. D. R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.682547 · Cited by 41
Miniotti, M., Lazzarin, G., Ortoncelli, M., Mastorino, L., Ribero, S., & Leombruni, P. (2022) · Dermatologic Therapy · doi:10.1111/dth.15407 · Cited by 34
The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases
Turchin, I., & Bourcier, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02241-y · Cited by 39
“Consistent with a pathogenic role of IL-4 and IL-13 in AD pathogenesis, dupilumab, which is an approved anti-IL-4Ra monoclonal antibody, improved AD signs and symptoms, including pruritus, and quality of life, compared to placebo in the SOLO 1 and SOLO 2 trials [70].”
BackgroundCritical Players and Therapeutic Targets in Chronic Itch
Hua, Y., Chen, W., Zhu, R., Wang, J., & Meng, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179935 · Cited by 35
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Trier, A. M., & Kim, B. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac016 · Cited by 33
The Impact of Air Pollution on Atopic Dermatitis
Lai, A., Owens, K. E., Patel, S., & Nicholas, M. W. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01095-w · Cited by 43
Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
Ko, E. M., & Chehade, M. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8674-3 · Cited by 33
Regulation of neutrophils in type 2 immune responses
Heeb, L. E. M., Egholm, C., Impellizzieri, D., Ridder, F., & Boyman, O. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.06.009 · Cited by 35
Dupilumab for the treatment of prurigo nodularis: A systematic review
Cao, P., Xu, W., Jiang, S., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092685 · Cited by 39
Silverberg, J. I., Strober, B. E., Feinstein, B., Xu, J., Guttman‐Yassky, E., Simpson, E. L., Li, P., Longphre, M. V., Song, J., Guo, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.924 · Cited by 33
Self-citationSpuls, P. I., Gerbens, L. A. A., Apfelbacher, C., Wall, D. R., Arents, B. W. M., Barbarot, S., Roberts, A., Deleuran, M. S., Middelkamp-Hup, M. A., Vestergaard, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.014 · Cited by 32
“Published by Elsevier, Inc. on b Journal of Investigative Dermatology (2017), Volum Administration (Beck et al., 2014; Simpson et al., 2016; Thaci et al., 2016); however, we need more evidence with regard to the effectiveness, safety, and cost effectiveness of such therapies compared with currently used treatment moda…”
BackgroundSelf-citationJang, D. H., Heo, S., Kook, H. D., Lee, D. H., Jung, H. J., Park, M. Y., & Ahn, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-02950-4 · Cited by 34
Sedeh, F. B., Henning, M. A. S., Jemec, G. B. E., & Ibler, K. S. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.2075 · Cited by 36
Impact of a Decade of Research Into Atopic Dermatitis
Arkwright, P. D., & Koplin, J. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.021 · Cited by 34
D’Erme, A. M., Romanelli, M., & Chiricozzi, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s113192 · Cited by 32
“33,43,48 Interestingly, mepolizumab (anti-IL-5) and omalizumab (anti-IgE), which have been studied in asthma with the same success as that of dupilumab, did not achieve enough results in AD.”
InfluentialDiagnosis and Management of Conjunctivitis for the Dermatologist
Gooderham, M., McDonald, J., & Papp, K. A. (2017) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475417743233 · Cited by 31
Endotypes of Chronic Rhinosinusitis Across Ancestry and Geographic Regions
Chitsuthipakorn, W., Seresirikachorn, K., Sommer, D., McHugh, T., & Snidvongs, K. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0800-z · Cited by 31
Tauber, M., Apoil, P. A., Richet, C., Laurent, J., de Bonnecaze, G., Mouchon, E., Cassagne, M., Marguery, M. C., Hegazy, S., Konstantinou, M. P., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17629 · Cited by 31
Lee, H. H., Patel, K. R., Rastogi, S., Singam, V., Vakharia, P. P., Chopra, R., & Silverberg, J. I. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.102 · Cited by 31
Self-citationDupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
Liberman, P., Shifera, A. S., & Berkenstock, M. (2020) · Cornea · doi:10.1097/ico.0000000000002262 · Cited by 32
Adult-Onset Atopic Dermatitis: Presentations and Progress
Chan, A. R., Sandhu, V. K., Drucker, A. M., Fleming, P., & Lynde, C. W. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420911896 · Cited by 35
Siegfried, E. C., Bieber, T. R. M., Simpson, E. L., Paller, A. S., Beck, L. A., Boguniewicz, M., Schneider, L. C., Khokhar, F. A., Chen, Z., Prescilla, R. P., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00583-3 · Cited by 37
Self-citationQuality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder
Agosta, E. D., Salvati, L., Corazza, M., Baiardini, I., Ambrogio, F., Angileri, L., Antonelli, E., Belluzzo, F., Bonamonte, D., Bonzano, L., et al. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00165-6 · Cited by 43
Stölzl, D., Sander, N., Heratizadeh, A., Haufe, E., Harder, I., Abraham, S., Heinrich, L., Kleinheinz, A., Wollenberg, A., Weißhaar, E., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21794 · Cited by 31
Self-citationGargiulo, L., Ibba, L., Cortese, A., Avagliano, J., Valenti, M., Costanzo, A., & Narcisi, A. (2023) · Dermatology and Therapy · doi:10.1007/s13555-022-00882-z · Cited by 32
“Dupilumab, a monoclonal antibody that targets the alpha subunit of the interleukin (IL)-4 receptor, blocking both IL-4 and IL-13 signaling, is currently approved for the treatment of AD in both adults and adolescents/children who are candidates for systemic treatment [9].”
BackgroundStänder, S., Luger, T. A., Kim, B., Lerner, E. A., Metz, M., Adiri, R., Canosa, J. M., Cha, A., & Yosipovitch, G. (2024) · Dermatology and Therapy · doi:10.1007/s13555-023-01081-0 · Cited by 34
“The monoclonal antibody dupilumab targets the a sub-unit of the IL-4 and IL-13 receptor complex, which has a known role in pruritis in AD [81, 99].”
BackgroundExecutive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2025) · Allergology International · doi:10.1016/j.alit.2025.01.003 · Cited by 37
Jha, M. K., Han, Y., Liu, Z., Hara, Y., Langohr, I. M., Morel, C., Maloney, C., Piepenhagen, P. A., Xing, H., Bodea, C. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.05.011 · Cited by 41
Novel topical and systemic therapies in atopic dermatitis
Suga, H., & Sato, S. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1642727 · Cited by 33
Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments
Beck, K. M., Seitzman, G. D., Yang, E., Sanchez, I. M., & Liao, W. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00465-3 · Cited by 32
Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis
Carnicle, J. M., Hendricks, A. J., & Shi, V. Y. (2019) · Dermatitis · doi:10.1097/der.0000000000000512 · Cited by 30
Punctal stenosis associated with dupilumab therapy for atopic dermatitis
Lee, D. H., Cohen, L. M., Yoon, M. K., & Tao, J. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1711010 · Cited by 30
“Interestingly, increased incidence of conjunctivitis in trials was observed during dupilumab treatment only for AD and not for other (Th2)-mediated diseases, implicating a dupilumab-AD specific interaction (4).”
BackgroundInfluentialPathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis
Furue, K., Ulzii, D., Tanaka, Y., Ito, T., Tsuji, G., Kido‐Nakahara, M., Nakahara, T., & Furue, M. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15507 · Cited by 33
Lunjani, N., Tan, G., Dreher, A., Sokołowska, M., Groeger, D., Wawrzyniak, M., Altunbulakli, C., Westermann, P., Basera, W., Hobane, L., et al. (2021) · Allergy · doi:10.1111/all.14974 · Cited by 31
Griffiths, C. E. M., de Bruin-Weller, M. S., Deleuran, M. S., Fargnoli, M. C., Staumont-Sallé, D., Hong, C.-H., Sánchez‐Carazo, J. L., Foley, P. A., Seo, S. J., Msihid, J., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00558-0 · Cited by 30
Self-citationCurrent Perspectives on the Systemic Management of Atopic Dermatitis
Davari, D. R., Nieman, E. L., McShane, D. B., & Morrell, D. S. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s287638 · Cited by 34
Therapeutic potential of biologics in prurigo nodularis
Müller, S., Bieber, T. R. M., & Ständer, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1958777 · Cited by 33
Self-citationZhang, L., Wen, X., Hou, Y., Yang, Y., Song, W., Zeng, Y., & Sun, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1002536 · Cited by 38
“The response rate of patients to dupilumab was 58% for EASI-75% at the end of the study period, which was higher than that reported in phase 3 clinical trials (EASI-75, 44%-51%) (22).”
Result(2023) · Australian Prescriber · doi:10.18773/austprescr · Cited by 30
Beck, L. A., Muraro, A. M., Boguniewicz, M., Chen, Z., Zahn, J., & Marco, A. R. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.08.005 · Cited by 34
Self-citationThe sensory neuroimmune frontier
Kim, B., & Artis, D. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.018 · Cited by 33
New treatments in atopic dermatitis update
Gallagher, K., Halperin-Goldstein, S., & Paller, A. S. (2025) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2025.06.020 · Cited by 32
Malik, K., & Guttman‐Yassky, E. (2017) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1016/j.jisp.2017.10.005 · Cited by 29
Self-citationRuíz‐Villaverde, R., Dominguez‐Cruz, J. J., Hita, J. C. A., Martínez-Pilar, L., Alcantara‐Luna, S., & Rodríguez, J. (2019) · Dermatologic Therapy · doi:10.1111/dth.12931 · Cited by 29
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis
Schneeweiss, M. C., Perez-Chada, L. M., & Merola, J. F. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.073 · Cited by 31
Wang, Y., & Jorizzo, J. L. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.042 · Cited by 30
Paller, A. S., Wollenberg, A., Siegfried, E. C., Thaçi, D., Cork, M. J., Arkwright, P. D., Gooderham, M., Sun, X., O’Malley, J. T., Khokhar, F. A., et al. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00459-x · Cited by 31
Self-citationRodríguez, J., Alcantara‐Luna, S., Dominguez‐Cruz, J. J., Galán‐Gutiérrez, M., Ruíz‐Villaverde, R., Vilar-Palomo, S., & Hita, J. C. A. (2021) · Life · doi:10.3390/life11090927 · Cited by 39
“For those drugs that have had different development for the adolescent and the adult population, the results have been similar [11,42].”
BackgroundResultInfluentialConnections between Immune-Derived Mediators and Sensory Nerves for Itch Sensation
Toyama, S., Tominaga, M., & Takamori, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212365 · Cited by 36
“Dupilumab, a monoclonal antibody that binds specifically to the shared alpha chain subunit of the IL-4 and IL-13 receptors, was associated with improvements in clinical end points, including reduced pruritus in AD [98].”
BackgroundCostedoat, I., Wallaert, M., Gaultier, A., Vasseur, R., Vanhaecke, C., Viguier, M. A., Cordelette, C., Denoyer, A., le Bouëdec, M. F., Coutu, A., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18932 · Cited by 30
Self-citationEmerging concepts in neuropathic and neurogenic itch
Auyeung, K. L., & Kim, B. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.08.008 · Cited by 31
Negative Regulation of Type 2 Immunity
de Kouchkovsky, D. A., Ghosh, S., & Rothlin, C. V. (2017) · Trends in Immunology · doi:10.1016/j.it.2016.12.002 · Cited by 29
“More recently, dupilumab, an antibody against the IL-4 receptor α subunit has demonstrated strong efficacy in patients with atopic dermatitis [64].”
BackgroundHamann, C. R., & Thyssen, J. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.018 · Cited by 30
Periostin and Dipeptidyl Peptidase-4
Emson, C. L., Pham, T., Manetz, S., & Newbold, P. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.06.004 · Cited by 30
Potential immunotherapies for sarcoidosis
Le, V. T., & Crouser, E. D. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1427727 · Cited by 33
“As such, Dupilumab can inhibit both IL-4 and IL-13 signaling, and has been used in moderate to severe asthma and atopic dermatitis with encouraging results [69,70].”
BackgroundImmune mediators and therapies for pruritus in atopic dermatitis and psoriasis
Yu, S., Li, Y., Zhou, Y., Follansbee, T., & Hwang, S. T. (2019) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12049 · Cited by 31
Critical Points on the Use of Biologicals in Allergic Diseases and Asthma
Agache, I. O., Cojanu, C., Laculiceanu, A. G., & Rogozea, L. M. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.1.24 · Cited by 29
Ribero, S., Giura, M. T., Viola, R., Ramondetta, A., Siliquini, N., Cardone, P., Tonella, L., Quaglino, P., Dapavo, P., Panzone, M., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16219 · Cited by 30
Type 2 immunity‐driven diseases: Towards a multidisciplinary approach
Hassoun, D., Malard, O., Barbarot, S., Magnan, A., & Colas, L. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14029 · Cited by 33
The pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
“In another phase 3 RCT (BREEZE-AD7), moderate-to-severe AD adults with an inadequate response to TCS therapy who received 4 mg of baricitinib plus TCS showed significant improvements in pruritus NRS by ≥4 points, the signs and symptoms of AD, sleep, skin pain, and QoL.”
BackgroundInfluentialRønnstad, A. T. M., Hansen, P. M., Halling, A., Egeberg, A., Kolko, M., Heegaard, S., & Thyssen, J. P. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17832 · Cited by 30
Achten, R., van Luijk, C., van der Rijst, L. P., Bakker, D. S., Spekhorst, L. S., Zuithoff, N. P. A., Schuttelaar, M. L. A., Romeijn, G. L. E., Voorberg, A. N., Kamsteeg, M., et al. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.1128 · Cited by 31
Pavel, A. B., DUCA, E. D., Cheng, J., Wu, J., Ungar, B., Estrada, Y. D., Jack, C. S., Maari, C., Proulx, É. S., Ramírez‐Valle, F., et al. (2022) · Allergy · doi:10.1111/all.15538 · Cited by 30
Self-citationStänder, S., Kwatra, S. G., Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Yosipovitch, G., Zhang, F., Cameron, M. C., Cella, R. R., Valdez, H., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00738-4 · Cited by 33
“Through selective inhibition of JAK1, abrocitinib directly inhibits the signaling of multiple inflammatory cytokines that are associated with inducing itch, including interleukin (IL)-31, IL-4, IL-13, and thymic stromal lymphopoietin (TSLP) [19–21].”
BackgroundResultInfluentialSelf-citationSilverberg, J. I., Bissonnette, R., Kircik, L., Murrell, D. F., Selfridge, A. C., Liu, K., Ahluwalia, G. S., & Guttman‐Yassky, E. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18914 · Cited by 31
Self-citationAtopic Dermatitis Yardstick update
Boguniewicz, M., Fonacier, L. S., Guttman‐Yassky, E., Ong, P. Y., & Silverberg, J. I. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.03.010 · Cited by 29
Self-citationSimpson, E. L., Silverberg, J. I., Thyssen, J. P., Viguier, M. A., Thaçi, D., de Bruin-Weller, M. S., Weidinger, S., Chan, G. L., DiBonaventura, M., Biswas, P., et al. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00785-5 · Cited by 31
“Dupilumab binds to the shared alpha chain subunit of the IL-4 and IL-13 receptors, thereby inhibiting the signalling of IL-4 and IL-13 [10].”
BackgroundSelf-citationSekita, A., Kawasaki, H., Fukushima‐Nomura, A., Yashiro, K., Tanese, K., Toshima, S., Ashizaki, K., Miyai, T., Yazaki, J., Kobayashi, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41857-8 · Cited by 36
Uses of biologics in allergic diseases
Saco, T. V., Pepper, A. N., & Casale, T. B. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.02.029 · Cited by 30
IL-4 Is a Key Requirement for IL-4- and IL-4/IL-13-Expressing CD4 Th2 Subsets in Lung and Skin
Prout, M. S., Kyle, R. L., Ronchese, F., & Gros, G. S. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01211 · Cited by 30
“Dupilumab that blocks IL4Rα, a subunit of both the IL-4 and IL-13 receptors, interferes with the action of both these cytokines and to date has had success in treating asthma and atopic dermatitis (42, 43).”
BackgroundCurrent and Emerging Therapies for Atopic Dermatitis in the Elderly
Teng, Y., Zhong, H., Yang, X., Tao, X., & Fan, Y. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s426044 · Cited by 31
Avallone, G., Cavallo, F., Tancredi, A., Maronese, C. A., Bertello, M., Fraghì, A., Conforti, C., Calabrese, G., Nicola, M. R. D., Oddenino, G. A., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19794 · Cited by 27
Use of biologics in severe food allergies
Fiocchi, A. G., Pecora, V., Valluzzi, R. L., Fierro, V., & Mennini, M. (2017) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000357 · Cited by 28
Advances in mechanisms of allergic disease in 2016
Rothenberg, M. E., Saito, H., & Peebles, R. S. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.029 · Cited by 29
Recalcitrant anal and genital pruritus treated with dupilumab
Yang, E., & Murase, J. E. (2018) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2018.08.010 · Cited by 27
“This biologic treatment inhibits IL-4– and IL-13–mediated inflammatory responses and has been shown in phase 3 trials to significantly decrease disease severity and risk of skin infections in patients affected with atopic dermatitis when given subcutaneously 300 mg every 2 weeks (Fleming and Drucker, 2018; Simpson et…”
BackgroundSiegfried, E. C., Igelman, S., Jaworsk, J. C., Antaya, R. J., Cordoro, K. M., Eichenfield, L. F., Levy, M. L., & Paller, A. S. (2019) · Pediatric Dermatology · doi:10.1111/pde.13707 · Cited by 27
“In both the case series performed by Treister and Lio and the phase 2a study,(1) patients treated with dupilumab had improvements in AD severity (investigator's global assessment, body surface area, Eczema Area and Severity Index, peak pruritus numeric rating scale) that were similar to those observed in adults.(2) We…”
Kim, J. E., Shin, M. K., Park, G., Lee, U. H., Lee, J. H., Han, T. Y., Ko, H., Jang, Y. H., Kim, H. O., Na, C. H., et al. (2019) · Annals of Dermatology · doi:10.5021/ad.2019.31.6.654 · Cited by 27
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
Li, G., Berkenstock, M., & Soiberman, U. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100848 · Cited by 27
Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Ahn, J., Choi, Y. S., & Simpson, E. L. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.1.1 · Cited by 30
Self-citationInborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate
Stadler, P., Renner, E. D., Milner, J. D., & Wollenberg, A. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.037 · Cited by 32
Self-citationNaidoo, K., Woods, K., Pellefigues, C., Cait, A., O’Sullivan, D., Gell, K., Marshall, A. J., Anderson, R. J., Li, Y., Schmidt, A., et al. (2021) · Allergy · doi:10.1111/all.14994 · Cited by 29
Agboola, F. O., Atlas, S. J., Brouwer, E., Carlson, J. J., Hansen, R. N., Herron-Smith, S., Nhan, E., Rind, D. M., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.1.108 · Cited by 32
Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
Wechsler, M. E., Souza‐Machado, A., Xu, C. R., Mao, X., Kapoor, U., Khokhar, F. A., O’Malley, J. T., Petro, C. D., Casullo, V. M., Mannent, L., et al. (2021) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2021.12.003 · Cited by 29
Kabata, H., Motomura, Y., Kiniwa, T., Kobayashi, T., & Moro, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8387-9_6 · Cited by 29
Yeom, M., Ahn, S., Jang, S.-Y., Jang, J., Lee, Y., Hahm, D., & Park, H. (2022) · Biological Research · doi:10.1186/s40659-022-00396-0 · Cited by 31
Treatment preferences among patients with mild-to-moderate atopic dermatitis
Myers, K., Silverberg, J. I., Parasuraman, S. V., Pierce, A., Eichenfield, L. F., & Poulos, C. M. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2215356 · Cited by 27
“The attributes were selected based on endpoints from clinical trials associated with approved and investigational therapies for mild-to-moderate AD [10–12], published data related to the treatment of AD, and prescribing information for currently available AD treatments [13–14].”
MethodSelf-citationLong-Term Treatment of Atopic Dermatitis
Prezzano, J. C., & Beck, L. A. (2017) · Dermatologic Clinics · doi:10.1016/j.det.2017.02.007 · Cited by 27
Self-citationZozaya, N., Martínez-Galdeano, L., Alcalá, B., Hita, J. C. A., Carmona, C., Carrascosa, J. M., Herranz, P., Lamas, M. J., Trapero‐Bertran, M., & Hidalgo‐Vega, Á. (2018) · BioDrugs · doi:10.1007/s40259-018-0284-3 · Cited by 27
“34), meaning that the pivotal trials from which the evidence came were deemed adequate [38, 39].”
BackgroundKim, M. H., Jin, S., Jang, S., Choi, J., Chung, D. H., Lee, D. H., Kim, K. H., & Kim, H. Y. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.447 · Cited by 29
Manfredini, M., Liberati, S., Ciardo, S., Bonzano, L., Guanti, M. B., Chester, J., Kaleci, S., & Pellacani, G. (2020) · Skin Research and Technology · doi:10.1111/srt.12868 · Cited by 29
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.